Evoke Pharma Announces Senior Leadership Transition With Promotion Of Matthew J. D'Onofrio To Chief Executive Officer, As Of March 31, 2024
Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, announced that Matthew J. D'Onofrio will be succeeding David A. Gonyer as Chief Executive Officer as of March 31, 2024 upon Mr. Gonyer's departure for personal reasons. Mr. D'Onofrio currently serves as President and Chief Operating Officer.
"Working closely with Dave has been an absolute privilege," said Matt D'Onofrio, incoming Chief Executive Officer of Evoke Pharma. "His relentless leadership resulted in our company developing and launching a highly unique and impactful therapy for patients suffering from diabetic gastroparesis. As CEO, I am driven by the same commitment to our core mission to bring GIMOTI to more and more patients who suffer from this devastating disease. Our strategy remains unaltered and our commercial team remains committed to ensure GIMOTI reaches those in need."
"Dave's vision and dedication have been the cornerstone of Evoke Pharma's success, turning the dream of GIMOTI into a life-changing reality for patients and for that, we are incredibly grateful to him," stated Cam Garner, Chairman of Evoke Pharma Board. "Given Matt has been an influential and integral part of the team since inception, the board and I share deep confidence in Matt's leadership for the future — a vision with ambitious commercial goals and intent to enhance value for our shareholders."
In tandem with his new executive responsibilities, Mr. D'Onofrio will assume Mr. Gonyer's board seat as of March 31, 2024.